Company: MIRM
Filing Date: 2025-08-06
Form Type: 10-Q
Source: 0001759425-25-000041
Chunk: 415

Company: Mirum Pharmaceuticals, Inc.
Filing Date: 2025-08-06
Form: 10-Q
Item: Part I, Item 8
Chunk 415
---
.7 million in advertising, promotion and medical affairs expenses associated with commercial activities, and $0.9 million of expenses associated with post marketing approval studies.

Interest Income

Interest income was $3.0 million for the three months ended June 30, 2025, a decrease of $0.5 million compared to the three months ended June 30, 2024 largely due to lower yields on investments. 

Interest Expense

Interest expense was $3.6 million for the three months ended June 30, 2025 and June 30, 2024, and related to interest expense incurred on our convertible notes.

27

Results of Operations for the Six Months Ended June 30, 2025 and 2024

The following table summarizes our results of operations for the six months ended June 30, 2025 and 2024 (in thousands): 

 Six Months Ended June 30,Change  20252024Revenue:Product sales, net$239,370 $146,677 $92,693 License and other revenue— 420 (420)Total revenue239,370 147,097 92,273 Operating expenses:Cost of sales46,439 38,057 8,382 Research and development92,111 64,894 27,217 Selling, general and administrative120,992 94,846 26,146 Total operating expenses259,542 197,797 61,745 Loss from operations(20,172)(50,700)30,528 Other income (expense):Interest income6,056 7,119 (1,063)Interest expense(7,185)(7,146)(39)Other income, net2,194 2,069 125 Net loss before provision for income taxes(19,107)(48,658)29,551 Provision for income taxes1,431 1,259 172 Net loss$(20,538)$(49,917)$29,379 

Product Sales, Net

Product sales, net was $239.4 million for the six months ended June 30, 2025, compared to $146.7 million for the six months ended June 30, 2024. The increase in product sales, net was a result of our continued commercialization of Livmarli in the U.S. for the treatment of ALGS and PFIC, and in certain international markets directly or through distributor and